Background: Metabolic syndrome (MS) refers to a group of cardiovascular risk factors associated with endothelial dysfunction and impaired coronary blood flow (CBF). Homocysteine (Hcy) is another risk factor for the development of insulin resistance and endothelial dysfunction. However, the relationship between Hcy levels and CBF in patients with MS has not been investigated specifically. In the present study, we aimed to evaluate the relationship between Hcy levels and CBF in MS patients with normal coronary arteries.
Methods: The study population included 36 patients with MS (20 males, 16 females; mean age = 55 ± 9 years) and 36 control subjects (20 males, 16 females; mean age = 51 ± 7 years). All subjects had angiographically proven normal coronary arteries. Plasma Hcy concentrations were evaluated after a fast of 12 h or longer. The CBF rates of all subjects were documented by the thrombolysis in myocardial infarction (TIMI) frame count method.
Results: The TIMI frame counts for each major epicardial coronary artery and mean TIMI frame count were found to be significantly higher in the MS group compared with the control group (left anterior descending coronary artery (LAD): 53 ± 26 vs. 39 ± 17; p = 0.01, left circumflex artery (LCx): 32 ± 12 vs. 26 ± 11; p = 0.01, right coronary artery (RCA): 33 ± 14 vs. 26 ± 12; p = 0.02, mean TIMI frame count: 39 ± 16 vs. 20 ± 12; p = 0.01). Plasma Hcy levels in patients with MS were significantly higher compared with controls (MS group = 11.6 ± 4 and control group = 9.6 ± 2.6; p = 0.01). Additionally, plasma Hcy levels were positively correlated with each calculated TIMI frame count value in the MS group (LAD, r: 0.28 and p = 0.006; LCx, r: 0.25 and p = 0.022; RCA, r: 0.26 and p = 0.042; mean TIMI frame count, r: 0.28 and p = 0.004).
Conclusion: Plasma Hcy levels and TIMI frame counts were significantly higher in patients with MS. Impaired CBF in MS may be related to elevated levels of Hcy, even if Hcy levels are normal.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00508-015-0854-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Short-term effects of upstream high bolus dose of tirofiban in patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Coron Artery Dis
January 2025
Department of Cardiovascular Medicine, Assiut University Heart Hospital, Assiut, Egypt.
Background: No-reflow following primary percutaneous coronary intervention (PPCI) is challenging to treat.
Objectives: The objective of this study is to evaluate the efficacy and safety of upstream high-bolus-dose tirofiban administration in ST-segment elevation myocardial infarction (STEMI) cases undergoing PPCI on top of dual antiplatelet therapy, including ticagrelor, in comparison to selective bailout administration.
Methods: This hospital-based, randomized, single-blinded prospective interventional study was conducted on 150 patients at Assiut University Heart Hospital.
TIMI frame count as a predictor of major adverse cardiovascular events during the first month after primary PCI.
Caspian J Intern Med
September 2024
Department of Cardiology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.
Article Synopsis
- This study examined the relationship between corrected Thrombolysis in Myocardial Infarction (TIMI) frame count (CTFC) and major adverse cardiovascular events (MACE) within a month after primary percutaneous coronary intervention (PPCI).
- The research included 80 patients at Ayatollah Rouhani Hospital, focusing on demographic data, coronary blood flow (CTFC), and the success of the intervention as indicated by ST segment resolution.
- Results showed no significant link between CTFC and MACE rates, although more than 50% ST segment resolution correlated with fewer cardiovascular events; ultimately, CTFC was deemed unreliable for predicting MACE in this timeframe.
Endocan may predict the presence of coronary slow flow and coronary artery disease.
Rev Assoc Med Bras (1992)
September 2024
Namık Kemal University, Faculty of Medicine, Department of Cardiology - Tekirdağ, Turkey.
Article Synopsis
- The study investigates the relationship between endocan levels and coronary artery disease (CAD) and coronary slow flow (CSF) in a group of 169 subjects undergoing coronary angiography.
- Both CAD and CSF patients exhibited significantly higher endocan levels compared to a control group, with similar levels between the two conditions, suggesting endocan's role in these diseases.
- Endocan levels, particularly when exceeding 450 pg/mL, are key predictors for both CAD and CSF, highlighting its potential as an important biomarker in these cardiovascular conditions.
The predictors of coronary slow flow in patients undergoing coronary angiography.
Egypt Heart J
August 2024
Faculty of Medicine, Mataram University, FK UNRAM, Jl. Pendidikan, No. 37, Mataram, NTB, Indonesia.
Background: A new challenge in coronary artery disease treatment has emerged, where specific populations exhibit ischemic symptoms without any obstruction in the epicardial coronary artery. Instead, they exhibit slow coronary contrast flow, referred to as coronary slow flow (CSF). This study aims to identify several predictors of CSF.
View Article and Find Full Text PDFMultimodality assessment of the coronary microvasculature with TIMI frame count versus perfusion PET highlights coronary changes characteristic of coronary microvascular disease.
Front Cardiovasc Med
June 2024
Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
Background: The diagnosis of coronary microvascular disease (CMVD) remains challenging. Perfusion PET-derived myocardial blood flow (MBF) reserve (MBFR) can quantify CMVD but is not widely available. Thrombolysis in Myocardial Infarction (TIMI) frame count (TFC) is an angiography-based method that has been proposed as a measure of CMVD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!